Tivity Health Delivers Strong Results For First Quarter 2021 With 141% Year Over Year Increase In Income From Continuing Operations
NASHVILLE, Tenn., May 5, 2021 /PRNewswire/ -- Tivity Health, Inc. (NASDAQ:TVTY), today announced financial results for the first quarter ended March 31, 2021.
Richard Ashworth, President and Chief Executive Officer, commented, "We delivered strong results for the first quarter of 2021, allowing us to tighten the ranges on revenue and Adjusted EBITDA guidance for the full year. We successfully expanded our SilverSneakers virtual offerings by launching a new Roku application for viewing on-demand content and are on track to deploy our omni-channel capabilities by the start of the third quarter. These strategic initiatives combined with the continued momentum in the number of in-person visits give us optimism for the remainder of the year. The recent additions of our new Chief Information Officer (CIO) and Chief Experience and Innovation Officer (CXIO) underline our commitment to quickly expand our member-centric engagement through a robust platform which includes digital and in-person experiences."
First Quarter Highlights
- Revenue from continuing operations was $108.1 million during the first quarter of 2021;
- Income from continuing operations was $19.9 million, an increase of $11.7 million, or 141%, over the prior year;
- Adjusted EBITDA from continuing operations was $41.2 million, representing an increase of $11.0 million, or 36%, compared to the prior year;
- In-person SilverSneakers gym visits totaled 11.2 million for Q1 2021, growing by 19% over the fourth quarter of 2020;
- Virtual SilverSneakers visits accelerated, totaling 1.2 million during the quarter, a 50% increase over the fourth quarter of 2020, with 36% of virtual visit participants being new to SilverSneakers;
- The Company ended the quarter with cash on hand of $52.4 million and a leverage ratio of 2.11, as calculated under its credit agreement. During the first quarter of 2021, the Company prepaid $63.6 million of principal and amortization of term loan debt. The Company's next quarterly installment is not due until December 2022;
- A new comprehensive scientific study conducted by Avalere Health showed that total average healthcare expenses for SilverSneakers participants were 16% lower compared to non-participating Medicare Advantage members.
First Quarter 2021 Financial Information
Dollars in millions, except per-share data
See pages 9-13 for a reconciliation of non-GAAP financial measures.
Three Months Ended March 31, | |||
2021 | 2020 | ||
Revenues from Continuing Operations | $108.1 | $159.7 | |
Income from Continuing Operations | $19.9 | $8.3 | |
Income from Continuing Operations Margin | 18.5% | 5.2% | |
Adjusted EBITDA from Continuing Operations | $41.2 | $30.2 | |
Adjusted EBITDA from Continuing Operations Margin | 38.1% | 18.9% | |
Diluted Earnings Per Share from Continuing Operations | $0.40 | $0.17 | |
Adjusted Diluted Earnings Per Share from Continuing Operations | $0.40 | $0.25 | |
Cash Flows from Operating Activities – former Healthcare segment (1) | $22.6 | $25.7 | |
Free Cash Flow – former Healthcare segment (1) | $19.4 | $22.5 | |
(1) | For comparability, figures for 2020 represent cash flows from the Company's former Healthcare segment. |
Revenues in the first quarter of 2021 of $108.1 million decreased $51.6 million, or approximately 32%, compared to the first quarter of 2020, primarily as a result of a significant decrease in SilverSneakers revenue of $41.8 million resulting from fewer revenue-generating visits due to the COVID-19 pandemic. Additionally, Prime Fitness revenue decreased by $10.2 million primarily due to terminations and suspensions.
The mix of SilverSneakers revenue during the first quarter of 2021 remained different from the mix during the first quarter of 2020 due to the reduction in fitness location visits resulting from the COVID-19 pandemic. Revenue from per-member-per-month fees represented 53% of the Company's SilverSneakers revenue in the first quarter of 2021, compared to 36% in the same quarter of 2020.
Income from continuing operations for the first quarter of 2021 was $19.9 million, an increase of $11.7 million compared to the first quarter of 2020. Adjusted EBITDA was $41.2 million for the first quarter, or 38.1% of revenues, compared to $30.2 million for the first quarter of 2020, or 18.9% of revenues. This improvement is primarily due to the mix of per-member-per-month fees for SilverSneakers driven by a reduction in fitness location visits and related costs for SilverSneakers and Prime, and also reflects a reduction in advertising expense and employee-related expenses.
During the first quarter, the Company prepaid $63.6 million of principal amortization on its term loan debt, and net debt (total debt less cash and cash equivalents) improved to $353 million, resulting in a net leverage ratio of 2.11. The Company's next quarterly installment is not due until December 2022.
Updated 2021 Financial Guidance
Tivity Health announced today that, based on first-quarter results and the Company's outlook for the remainder of 2021, it has updated its financial guidance as follows:
Dollars in millions, except per-share data
February 24, 2021 (Prior Guidance) | May 5, 2021 (Updated Guidance) | |
Revenues | $455 - $485 | $465 - $485 |
Income from Continuing Operations | $70.5 - $74.3 | $71.3 - $74.3 |
Adjusted EBITDA (1) | $150 - $155 | $151 - $155 |
Depreciation Expense | Approximately $14 | Unchanged |
Interest Expense | Approximately $37, including $6 of non-cash | Unchanged |
Effective Tax Rate | Approximately 25% | Unchanged |
Weighted Average Diluted Shares Outstanding | 50.0 million – 50.5 million | Unchanged |
Earnings per Diluted Share | $1.40 - $1.49 | $1.41 - $1.49 |
Adjusted Earnings per Diluted Share (1) | $1.47 - $1.56 | $1.49 - $1.56 |
Cash Flows from Operating Activities | $81 - $85 | Unchanged |
Free Cash Flow (1) | $50 - $60 | Unchanged |
Capital Expenditures | $20 - $25 | Unchanged |
Tivity Health's detailed guidance considerations for 2021 may be found in the supplemental information posted on the Company's website at http://investors.tivityhealth.com.
(1) | Adjusted EBITDA, adjusted earnings per diluted share, and free cash flow are non-GAAP financial measures. See pages 9-13 for a reconciliation of non-GAAP financial measures. |
Conference Call
Tivity Health will hold a conference call to discuss this release today at 5:00 p.m. Eastern Time. Investors will have the opportunity to listen to the conference call live by dialing 877-683-2218 or 647-689-5447 for international callers, and referencing code 4896873 or over the Internet by going to www.tivityhealth.com and clicking "Investors" at least 15 minutes early to register, download, and install any necessary audio software. For those who cannot listen to the live broadcast, a telephonic replay will be available for one week at 800-585-8367 or 416-621-4642 for international callers, code 4896873, and the replay will also be available on the Company's web site for the next 7 months.
About Tivity Health
Tivity Health® Inc. (NASDAQ:TVTY) is a leading provider of healthy life-changing solutions, including SilverSneakers®, Prime® Fitness, WholeHealth Living® and Wisely Well™. We are focused on becoming the modern destination for healthy living. We will expand beyond fitness by establishing an engagement platform that enables personalized member interaction with all of our offerings, and we will partner with other payors and service providers to aggregate services to seniors under the SilverSneakers umbrella. The continued development of our suite of digital offerings will enable a more tailored, interactive, and impactful experience across a variety of areas, including fitness, social connection, community involvement, volunteering, and enrichment. Learn more at www.tivityhealth.com.
Non-GAAP Financial Measures
This press release contains certain non-GAAP financial measures. Reconciliations of certain of these non-GAAP measures to the comparable GAAP measures are included on pages 9-13.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain statements that are "forward-looking" statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based upon current expectations and include all statements that are not historical statements of fact and those regarding the intent, belief or expectations, including, without limitation, statements that are accompanied by words such as "will," "expect," "outlook," "anticipate," "intend," "plan," "believe," "seek," "see," "would," "target," or other similar words, phrases or expressions and variations or negatives of these words. These forward-looking statements include, but are not limited to, the Company's statements regarding its future financial performance. Readers of this press release should understand that these statements are not guarantees of performance or results. Many risks and uncertainties could affect actual results and cause them to vary materially from the forward-looking statements.
These risks and uncertainties include, among other things: impacts from the COVID-19 pandemic (including the response of governmental authorities to combat and contain the pandemic, the closure of fitness centers in the Company's national network (or operational restrictions imposed on such fitness centers), reclosures and potential additional reclosures as a result of surges in positive COVID-19 cases) on the Company's business, operations or liquidity; the risks associated with changes in macroeconomic conditions (including the impacts of any recession or changes in consumer spending resulting from the COVID-19 pandemic), widespread epidemics, pandemics (such as the current COVID-19 pandemic) or other outbreaks of disease, geopolitical turmoil, and the continuing threat of domestic or international terrorism; the Company's ability to collect accounts receivable from its customers and amounts due under its sublease agreements; the market's acceptance of the Company's new products and services; the Company's ability to develop and implement effective strategies and to anticipate and respond to strategic changes, opportunities, and emerging trends in the Company's industry and/or business, as well as to accurately forecast the related impact on the Company's revenues and earnings; the impact of any impairment of the Company's goodwill, intangible assets, or other long-term assets; the Company's ability to attract, hire, or retain key personnel or other qualified employees and to control labor costs; the effectiveness of the reorganization of the Company's business and the Company's ability to realize the anticipated benefits; the Company's ability to effectively compete against other entities, whose financial, research, staff, and marketing resources may exceed its resources; the impact of legal proceedings involving the Company and/or its subsidiaries, products, or services, including any claims related to intellectual property rights, as well as our ability to maintain insurance coverage with respect to such legal proceedings and claims on terms that would be favorable to us; the impact of severe or adverse weather conditions, the current COVID-19 pandemic, and the potential emergence of additional health pandemics or infectious disease outbreaks on member participation in the Company's programs; the risks associated with deriving a significant concentration of revenues from a limited number of the Company's customers, many of whom are health plans; the Company's ability and/or the ability of its customers to enroll participants and to accurately forecast their level of enrollment and participation in the Company's programs in a manner and within the timeframe anticipated by the Company; the Company's ability to sign, renew and/or maintain contracts with its customers and/or the Company's fitness partner locations under existing terms or to restructure these contracts on terms that would not have a material negative impact on the Company's results of operations; the ability of the Company's health plan customers to maintain the number of covered lives enrolled in those health plans during the terms of the Company's agreements; the Company's ability to add and/or retain active subscribers in its Prime Fitness program; the impact of any changes in tax rates, enactment of new tax laws, revisions of tax regulations or any claims or litigation with taxing authorities; the impact of a reduction in Medicare Advantage health plan reimbursement rates or changes in plan design; the impact of any new or proposed legislation, regulations and interpretations relating to Medicare, Medicare Advantage, Medicare Supplement, and privacy and security laws; the impact of healthcare reform on the Company's business; the risks associated with potential failures of the Company's information systems or those of our third-party vendors, including as a result of telecommuting issues associated with the Company's employees working remotely, which may include a failure to execute on policies and processes in a work-from-home or remote model; the risks associated with data privacy or security breaches, computer hacking, network penetration and other illegal intrusions of the Company's information systems or those of third-party vendors or other service providers, including those risks that result from the increase in personnel working remotely, which may result in unauthorized access by third parties, loss, misappropriation, disclosure or corruption of customer, employee or the Company's information, or other data subject to privacy laws and may lead to a disruption in the Company's business, costs to modify, enhance, or remediate its cybersecurity measures, enforcement actions, fines or litigation against the Company, or damage to its business reputation; the risks associated with changes to traditional office-centered business processes and/or conducting operations out of the office in a work-from-home or remote model by us or our third party vendors during adverse situations (e.g., during a crisis, disaster, or pandemic), which may result in additional costs and/or may negatively impact productivity and cause other disruptions to the Company's business; the Company's ability to enforce its intellectual property rights; the risk that the Company's indebtedness may limit the Company's ability to adapt to changes in the economy or market conditions, expose the Company to interest rate risk for the variable rate indebtedness and require a substantial portion of cash flows from operations to be dedicated to the payment of indebtedness; the Company's ability to service its debt, make principal and interest payments as those payments become due, and remain in compliance with its debt covenants; the Company's ability to obtain adequate financing to provide the capital that may be necessary to support its current or future operations; counterparty risk associated with the Company's interest rate swap agreements; and other risks detailed in the Company's filings with the Securities and Exchange Commission.
For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's filings with the SEC. Except as required by law, the Company undertakes no obligation to update any such forward-looking statements to reflect new information, subsequent events or circumstances.
TIVITY HEALTH, INC. CONSOLIDATED BALANCE SHEETS (In thousands, except share and per share data) (Unaudited) | ||||||||
March 31, 2021 | December 31, 2020 | |||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 52,428 | $ | 100,385 | ||||
Accounts receivable, net | 44,959 | 25,981 | ||||||
Prepaid expenses | 4,154 | 5,556 | ||||||
Income taxes receivable | 779 | 10,996 | ||||||
Other current assets | 19,586 | 11,336 | ||||||
Total current assets | 121,906 | 154,254 | ||||||
Property and equipment, net of accumulated depreciation of $40,713 and $38,188 respectively | 19,981 | 20,959 | ||||||
Right-of-use assets | 16,288 | 18,139 | ||||||
Long-term deferred tax asset | 1,186 | 3,601 | ||||||
Intangible assets, net | 29,049 | 29,049 | ||||||
Goodwill, net | 334,680 | 334,680 | ||||||
Other assets | 16,808 | 18,301 | ||||||
Total assets | $ | 539,898 | $ | 578,983 | ||||
Current liabilities: | ||||||||
Accounts payable | $ | 18,400 | $ | 19,741 | ||||
Accrued salaries and benefits | 5,264 | 8,949 | ||||||
Accrued liabilities | 31,395 | 18,424 | ||||||
Deferred revenue | 4,351 | 4,460 | ||||||
Current portion of long-term debt | 7,456 | 7,456 | ||||||
Current portion of lease liabilities | 8,064 | 8,052 | ||||||
Current portion of other long-term liabilities | 14,195 | 14,753 | ||||||
Total current liabilities | 89,125 | 81,835 | ||||||
Long-term debt | 397,750 | 459,250 | ||||||
Long-term lease liabilities | 9,460 | 11,494 | ||||||
Other long-term liabilities | 17,309 | 22,748 | ||||||
Commitments and contingent liabilities | ||||||||
Stockholders' equity: | ||||||||
Preferred stock $.001 par value, 5,000,000 shares authorized, none outstanding | — | — | ||||||
Common Stock $.001 par value, 120,000,000 shares authorized, 49,246,281 and 48,983,735 shares outstanding, respectively | 49 | 49 | ||||||
Additional paid-in capital | 513,923 | 513,263 | ||||||
Accumulated deficit | (444,949) | (464,085) | ||||||
Treasury stock, at cost, 2,254,953 shares in treasury | (28,182) | (28,182) | ||||||
Accumulated other comprehensive loss | (14,587) | (17,389) | ||||||
Total stockholders' equity | 26,254 | 3,656 | ||||||
Total liabilities and stockholders' equity | $ | 539,898 | $ | 578,983 | ||||
TIVITY HEALTH, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except earnings per share data) (Unaudited) | |||||||||
Three Months Ended March 31, | |||||||||
2021 | 2020 | ||||||||
Revenues | $ | 108,085 | $ | 159,692 | |||||
Cost of revenue (exclusive of depreciation of $2,531 and $1,831, respectively, included below) | 57,285 | 115,148 | |||||||
Marketing expense | 1,231 | 7,299 | |||||||
Selling, general and administrative expenses | 9,696 | 12,052 | |||||||
Depreciation expense | 2,683 | 2,030 | |||||||
Restructuring and related charges | — | 482 | |||||||
Operating income | 37,190 | 22,681 | |||||||
Interest expense | 10,756 | 11,270 | |||||||
Other (income) expense, net | (1,130) | — | |||||||
Total non-operating expense, net | 9,626 | 11,270 | |||||||
Income before income taxes | 27,564 | 11,411 | |||||||
Income tax expense | 7,620 | 3,136 | |||||||
Income from continuing operations | $ | 19,944 | $ | 8,275 | |||||
Loss from discontinued operations, net of income tax benefit of $277 and $18,282, respectively | (808) | (206,381) | |||||||
Net income (loss) | $ | 19,136 | $ | (198,106) | |||||
Earnings (loss) per share - basic: | |||||||||
Continuing operations | $ | 0.41 | $ | 0.17 | |||||
Discontinued operations | $ | (0.02) | $ | (4.25) | |||||
Net income (loss) | $ | 0.39 | $ | (4.08) | |||||
Earnings (loss) per share - diluted: | |||||||||
Continuing operations | $ | 0.40 | $ | 0.17 | |||||
Discontinued operations | $ | (0.02) | $ | (4.22) | |||||
Net income (loss) | $ | 0.38 | $ | (4.05) | |||||
Comprehensive income (loss) | $ | 21,938 | $ | (217,935) | |||||
Weighted average common shares and equivalents: | |||||||||
Basic | 49,222 | 48,613 | |||||||
Diluted | 50,340 | 48,855 | |||||||
TIVITY HEALTH, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited) | ||||||||
Three Months Ended March 31, | ||||||||
2021 | 2020 | |||||||
Cash flows from operating activities: | ||||||||
Income from continuing operations | $ | 19,944 | $ | 8,275 | ||||
Loss from discontinued operations | (808) | (206,381) | ||||||
Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
Depreciation and amortization | 2,683 | 14,763 | ||||||
Amortization and write-off of deferred loan costs | 1,183 | 1,212 | ||||||
Amortization and write-off of debt discount | 1,077 | 1,095 | ||||||
Share-based employee compensation expense | 2,998 | 824 | ||||||
Gain on derivatives | (1,130) | — | ||||||
Impairment of goodwill and intangible assets of discontinued operation | — | 199,500 | ||||||
Deferred income taxes | 1,454 | (16,031) | ||||||
(Increase) decrease in accounts receivable, net | (18,978) | 16,665 | ||||||
Decrease in income taxes receivable | 10,217 | — | ||||||
Decrease in inventory | — | 4,057 | ||||||
Decrease in other current assets | 529 | 4,746 | ||||||
(Decrease) increase in accounts payable | (42) | 12,612 | ||||||
Decrease in accrued salaries and benefits | (3,685) | (4,852) | ||||||
Increase in other current liabilities | 5,594 | 5,501 | ||||||
(Decrease) increase in deferred revenue | (109) | 3,247 | ||||||
Other | 1,691 | 1,790 | ||||||
Net cash flows provided by operating activities | $ | 22,618 | $ | 47,023 | ||||
Cash flows from investing activities: | ||||||||
Acquisition of property and equipment | $ | (1,561) | $ | (4,875) | ||||
Settlement on derivatives not designated as hedges | (1,633) | — | ||||||
Net cash flows used in investing activities | $ | (3,194) | $ | (4,875) | ||||
Cash flows from financing activities: | ||||||||
Proceeds from issuance of long-term debt | $ | — | $ | 160,325 | ||||
Payments of long-term debt | (63,600) | (123,000) | ||||||
Payments related to tax withholding for share-based compensation | (2,502) | (2,795) | ||||||
Exercise of stock options | 164 | 601 | ||||||
Change in cash overdraft and other | (1,443) | 3,269 | ||||||
Net cash flows (used in) provided by financing activities | $ | (67,381) | $ | 38,400 | ||||
Net (decrease) increase in cash and cash equivalents | $ | (47,957) | $ | 80,548 | ||||
Cash and cash equivalents, beginning of period | $ | 100,385 | $ | 2,486 | ||||
Cash and cash equivalents, end of period | $ | 52,428 | $ | 83,034 | ||||
TIVITY HEALTH, INC. | |||||||||||
Reconciliation of Income from Continuing Operations, GAAP Basis to | |||||||||||
Three Months Ended March 31, 2021 |
% of | Three Months March 31, 2020 |
% of | ||||||||
Income from continuing operations, GAAP basis | $ | 19,944 | 18.5% | $ | 8,275 | 5.2% | |||||
Depreciation expense | 2,683 | 2,030 | |||||||||
Interest expense | 10,756 | 11,270 | |||||||||
Income tax expense | 7,620 | 3,136 | |||||||||
EBITDA from continuing operations, non-GAAP basis (1) | $ | 41,003 | $ | 24,711 | |||||||
Acquisition, integration, project, and CEO transition costs (2) | 1,321 | 5,049 | |||||||||
Restructuring charges (3) | — | 482 | |||||||||
Other (income)/expense (4) | (1,130) | — | |||||||||
Adjusted EBITDA from continuing operations, non-GAAP basis (5) | $ | 41,194 |
38.1% | $ | 30,242 |
18.9% | |||||
(1) | EBITDA from continuing operations is a non-GAAP financial measure. The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management. You should not consider EBITDA from continuing operations in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP. |
(2) | Acquisition, integration, project, and CEO transition costs consist of pre-tax charges of $1,321 and $5,049 for the three months ended March 31, 2021 and 2020, respectively, primarily incurred in connection with the acquisition and integration of Nutrisystem and with the termination of the Company's former CEO in February 2020 and the hiring of a new CEO in June 2020. |
(3) | Restructuring charges consist of pre-tax charges of $482 for the three months ended March 31, 2020, primarily related to a restructuring of corporate support infrastructure and of executive leadership. |
(4) | Other (income)/expense consists of pre-tax income of $1,130 related to certain interest rate swap agreements that do not qualify for hedge accounting treatment ("de-designated swaps") and require changes in fair value to be recognized each period in current earnings. |
(5) | Adjusted EBITDA from continuing operations is a non-GAAP financial measure. The Company excludes acquisition, integration, project, and CEO transition costs, restructuring charges, and other (income)/expense from this measure because of its comparability to the Company's historical operating results. The Company updated its definition of adjusted EBITDA during the first quarter of 2021 to exclude other (income)/expense related to de-designated swaps. The Company considers such (income)/expense to be outside the performance of its ongoing core business operations and believes that presenting Adjusted EBITDA excluding other (income)/expense provides increased transparency as to the operating costs of its current business performance. The Company did not revise the prior period's Adjusted EBITDA amounts because there were no costs similar in nature to these items. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management. You should not consider Adjusted EBITDA from continuing operations in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP. Additionally, because Adjusted EBITDA from continuing operations may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies. |
Reconciliation of Income from Continuing Operations Guidance, GAAP Basis to | ||||||
Year Ending December 31, 2021 | ||||||
Income from continuing operations guidance, GAAP basis | $71.3 - $74.3 | |||||
Depreciation expense | 14 | |||||
Interest expense | 37 | |||||
Income tax expense | 23.8 – 24.8 | |||||
EBITDA from continuing operations, non-GAAP basis (6) | $146 - $150 | |||||
Integration, project, and CEO transition costs (7) | 5 | |||||
Adjusted EBITDA from continuing operations guidance, non-GAAP basis (8) | $151 - $155 | |||||
(6) | EBITDA from continuing operations guidance is a non-GAAP financial measure. The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management. You should not consider EBITDA from continuing operations guidance in isolation or as a substitute for income from continuing operations determined in accordance with U.S. GAAP. Figures may not add due to rounding. |
(7) | Integration, project, and CEO transition costs primarily relate to strategic projects and the Company's transition to a new CEO during 2020. |
(8) | Adjusted EBITDA from continuing operations guidance is a non-GAAP financial measure. The Company excludes integration, project, and CEO transition costs from this measure because of its comparability to the Company's historical operating results. The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management. You should not consider Adjusted EBITDA from continuing operations guidance in isolation or as a substitute for income from continuing operations guidance determined in accordance with U.S. GAAP. Additionally, because Adjusted EBITDA from continuing operations guidance may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies. |
Reconciliation of Net Cash Flows Provided by Operations, GAAP Basis to | |||||||||
Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | ||||||||
Net cash flows provided by operations, GAAP basis | $ | 22,618 | $ | 47,023 | |||||
Acquisition of property and equipment | (1,561) | (4,875) | |||||||
Settlement on derivatives not designated as hedges | (1,633) | — | |||||||
Free cash flow, non-GAAP basis (9) | $ | 19,424 | $ | 42,148 | |||||
(9) | Free cash flow is a non-GAAP financial measure and is defined by the Company as net cash flows provided by operating activities less acquisition of property and equipment and settlement on derivatives not designated as hedges. The Company updated its definition of free cash flow during the fourth quarter of 2020 to exclude settlement on derivatives not designated as hedges. The Company considers these costs to be a reduction of cash available for other uses and believes that presenting free cash flow excluding settlement on derivatives provides increased transparency. The Company did not revise prior periods' free cash flow because there were no costs similar in nature to this item. The Company believes free cash flow is a useful measure of performance and an indication of the strength of the Company and its ability to generate cash. The Company believes it is useful to investors to provide disclosures of its results on the same basis as that used by management. You should not consider free cash flow in isolation or as a substitute for net cash flows provided by operating activities determined in accordance with U.S. GAAP. Additionally, because free cash flow may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies. |
Reconciliation of Net Cash Flows Provided by Operations from Former Healthcare Segment, GAAP Basis | |||||||||
Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | ||||||||
Net cash flows provided by operations from former Healthcare segment, GAAP basis | $ | 22,618 | $ | 25,735 | |||||
Acquisition of property and equipment | (1,561) | (3,193) | |||||||
Settlement on derivatives not designated as hedges | (1,633) | — | |||||||
Free cash flow from former Healthcare segment, non-GAAP basis (10) | $ | 19,424 | $ | 22,542 | |||||
(10) | Free cash flow from former Healthcare segment is a non-GAAP financial measure and is defined by the Company as net cash flows provided by operating activities less acquisition of property and equipment and settlement on derivatives not designated as hedges. The Company updated its definition of free cash flow during the fourth quarter of 2020 to exclude settlement on derivatives not designated as hedges. The Company considers these costs to be a reduction of cash available for other uses and believes that presenting free cash flow excluding settlement on derivatives provides increased transparency. The Company did not revise prior periods' free cash flow because there were no costs similar in nature to this item. The Company believes free cash flow is a useful measure of performance and an indication of the strength of the Company and its ability to generate cash. The Company believes it is useful to investors to provide disclosures of its results on the same basis as that used by management. You should not consider free cash flow from former Healthcare segment in isolation or as a substitute for net cash flows provided by operating activities determined in accordance with U.S. GAAP. Additionally, because free cash flow may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies. |
Reconciliation of Net Cash Flows Provided by Operations Guidance, GAAP Basis to | ||||||
Year Ending December 31, 2021 | ||||||
Net cash flows provided by operations guidance, GAAP basis | $ | 81 - 85 | ||||
Acquisition of property and equipment guidance | (25 - 20) | |||||
Settlement on derivatives not designated as hedges guidance | (6 - 5) | |||||
Free cash flow guidance, non-GAAP basis (11) | $ | 50 - 60 | ||||
(11) | Free cash flow guidance is a non-GAAP financial measure and is defined by the Company as net cash flows provided by operating activities less acquisition of property and equipment and settlement on derivatives not designated as hedges. The Company believes free cash flow is a useful measure of performance and an indication of the strength of the Company and its ability to generate cash. The Company believes it is useful to investors to provide disclosures of its results and guidance on the same basis as that used by management. You should not consider free cash flow guidance in isolation or as a substitute for net cash flows provided by operating activities guidance determined in accordance with U.S. GAAP. Additionally, because free cash flow may be defined differently by other companies in the Company's industry, the non-GAAP financial measure presented here may not be comparable to similarly titled measures of other companies. |
Reconciliation of Earnings Per Share ("EPS") from Continuing Operations, GAAP Basis to | ||||||||
Three Months Ended March 31, 2021 | Three Months Ended March 31, 2020 | |||||||
EPS from continuing operations, GAAP basis | $ | 0.40 | $ | 0.17 | ||||
Net loss per share attributable to acquisition, integration, project, CEO transition, and restructuring costs (12) | 0.02 | 0.08 | ||||||
Net income per share attributable to other (income)/expense (13) | (0.02) | — | ||||||
Adjusted EPS from continuing operations, non-GAAP basis (14) | $ | 0.40 | $ | 0.25 | ||||
(12) | Net loss attributable to acquisition, integration, project, CEO transition, and restructuring costs consists of pre-tax charges of $1,321 and $5,531 for the three months ended March 31, 2021 and 2020, respectively. These costs primarily related to the acquisition and integration of Nutrisystem, the termination of our former CEO in February 2020 and hiring of our new CEO in June 2020, and restructuring activities as described in Note 3 above. The tax rate applied to these charges was 25%, which represented the combined estimated U.S. federal and state statutory tax rate. |
(13) | Net income attributable to other (income)/expense consists of pre-tax income of $1,130 for the three months ended March 31, 2021 related to de-designated swaps, as described in Note 4 above. The tax rate applied to this income was 25%, which represented the combined estimated U.S. federal and state statutory tax rate |
(14) | Adjusted EPS from continuing operations is a non-GAAP financial measure. The Company excludes net (income) loss per share attributable to acquisition, integration, CEO transition, and restructuring costs and other (income)/expense from this measure because of its comparability to the Company's historical operating results. The Company believes it is useful to investors to provide disclosures of its operating results on the same basis as that used by management. You should not consider adjusted EPS from continuing operations in isolation or as a substitute for EPS from continuing operations determined in accordance with U.S. GAAP. Additionally, because adjusted EPS from continuing operations may be defined differently by other companies in the Company's industry, the non-GAAP financial measures presented here may not be comparable to similarly titled measures of other companies. |
Reconciliation of EPS from Continuing Operations Guidance, GAAP Basis to Adjusted EPS from | |||||
Year Ending December 31, | |||||
EPS from continuing operations guidance, GAAP basis | $1.41 - $1.49 | ||||
Net loss per share attributable to restructuring, integration project, and CEO transition costs guidance (15) | 0.07 | ||||
Adjusted EPS from continuing operations guidance, non-GAAP basis (16) | $ | $1.49 – 1.56 | |||
(15) | Net loss per share attributable to restructuring, integration, project, and CEO transition costs guidance consists of pre-tax charges of $5,000 for the year ending December 31, 2021. These costs primarily relate to strategic projects, the Company's transition to a new CEO during 2020, and restructuring activities. The tax rate applied to these charges was 25%, which represents the combined estimated U.S. federal and state statutory tax rate. |
(16) | Adjusted EPS from continuing operations guidance is a non-GAAP financial measure. The Company excludes net loss attributable to restructuring, project, and CEO transition costs from this measure because of its comparability to the Company's historical operating results. The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management. You should not consider adjusted EPS from continuing operations guidance in isolation or as a substitute for EPS from continuing operations guidance determined in accordance with U.S. GAAP. Additionally, because adjusted EPS from continuing operations guidance may be defined differently by other companies in the Company's industry, the non-GAAP financial measures presented here may not be comparable to similarly titled measures of other companies. Figures may not add due to rounding. |
Reconciliation of Total Debt, GAAP Basis | |||||||||
March 31, 2021 | March 31, 2020 | ||||||||
Total debt, GAAP basis | $ | 405,206 | $ | 1,087,599 | |||||
Cash and cash equivalents | (52,428) | (83,034) | |||||||
Net debt, non-GAAP basis (17) | $ | 352,778 | $ | 1,004,565 | |||||
(17) | Net debt is a non-GAAP financial measure. The Company excludes cash and cash equivalents from this measure and believes that net debt is an important measure to monitor its leverage and evaluate the balance sheet. The Company believes it is useful to investors to provide disclosures of its financial position on the same basis as that used by management. You should not consider net debt in isolation or as a substitute for total debt determined in accordance with U.S. GAAP. Additionally, because net debt may be defined differently by other companies in the Company's industry, the non-GAAP financial measures presented here may not be comparable to similarly titled measures of other companies. |
View original content:http://www.prnewswire.com/news-releases/tivity-health-delivers-strong-results-for-first-quarter-2021-with-141-year-over-year-increase-in-income-from-continuing-operations-301284908.html
SOURCE Tivity Health, Inc.